A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Shakthi Kumar, EDETEK, Inc.'s Chief Strategy and Business Officer, explores the company's launch of R&D Cloud.

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

Direct-to-consumer advertising can be a controversial topic in the pharma industry. While the US isn’t the only other country ...

The two organizations will provide multi-modal learning experiences, opportunities to work with peers, and more.

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve overall survival in patients with advanced of metastatic non-small cell lung ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

In early phase trials innovative designs offer potential for improvements in efficiency and decision-making. Determining the ...

Many companies and investors believe that AI has to potential to reshape various elements of the pharma industry. Two ...